drugset
drugset / Trial / NCT06936527

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

NCT06936527 ↗

Phase 1/2 Enrolling by invitation 102 enrolled NovaOnco Therapeutics Co., Ltd.
RandomizedSequentialOpen-labelTreatment

Summary

XS-03 in combination with FOLFOX or FOLFIRI and Bevacizumab for treatment of metastatic colorectal cancer patients with RAS mutation

Timeline

Start
2025-05-23
Primary completion
2028-04-30
Completion
2028-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject XS-03 Unknown — Oral
Comparator Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Background Irinotecan Small molecule 180 mg/m2 Intravenous
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background fluorouracil Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

colorectal cancer